Articles Alert

DENNIS P. CURRAN Department of Chemistry University of Pittsburgh Pittsburgh, Pa. Like its natural predecessors FK506 and rapamycin, a non-natural immunophilin ligand (506BD) is a potent inhibitor of the FK506 binding protein's rotomase activity. However, unlike the natural compounds, the nonnatural analog does not interfere with T cell activation. Thus, inhibition of rotamase activity is an insufficient requirement for immunosuppressant action. B.E. Bierer, P.K. Somers, T.J. Wandless, S.J. B

Written byDennis Curran
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

DENNIS P. CURRAN

Department of Chemistry
University of Pittsburgh
Pittsburgh, Pa.

Like its natural predecessors FK506 and rapamycin, a non-natural immunophilin ligand (506BD) is a potent inhibitor of the FK506 binding protein's rotomase activity. However, unlike the natural compounds, the nonnatural analog does not interfere with T cell activation. Thus, inhibition of rotamase activity is an insufficient requirement for immunosuppressant action.

B.E. Bierer, P.K. Somers, T.J. Wandless, S.J. Burakoff, S.L. Schreiber, "Probing immunosuppressant action with a non-natural immunophilin ligand," Science, 250, 556-7, 26 October 1990. (Brigham and Women's Hospital, Boston; Dana-Farber Cancer Institute, Boston; Harvard University, Cambridge, Mass.)

Most chemists try to avoid getting their research all tied up in knots. But knots can indeed be beautiful, as illustrated by the X-ray crystal structure of a remarkable synthetic molecule.

C.O. Dietrich-Buchecker, J. Guilham, C. Pascard, J.-P. Sauvage, "Structure of a synthetic trefoil knot coordinated to two copper(I) centers," Angewandte Chemie, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies